# Patient Dies After Gene Editing Trial in China 2026-08-07T05:51:03+00:00 | Health & Science | Indian Opinion Desk Corroboration: 1 independent outlet A patient with Duchenne muscular dystrophy died after receiving a gene editing therapy from Shanghai-based HuidaGene Therapeutics, the company said on Wednesday. The death occurred in August 2025 and was attributed to acute respiratory distress syndrome during a severe immune reaction to the treatment. HuidaGene did not identify the patient or provide further details. Clinical trial records suggest the study enrolled boys aged four to eight. The Times of India reports that the disclosure followed a months-long probe by STAT News. Science had also reported the previously unreported death of a girl in a separate investigator-led trial. Chinese authorities have launched probes into the cases. ## Coverage - timesofindia.indiatimes.com Tags: China biotech, clinical trials, drug safety, Duchenne muscular dystrophy, gene editing Canonical: https://indianopinion.org/patient-dies-after-gene-editing-trial-in-china/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/patient-dies-after-gene-editing-trial-in-china/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes.